ISIS Pharm (NASDAQ:ISIS) Reaching An Inflection Point; Wells Fargo Coverage Initiated as “Outperform”


How Wells Fargo Currently Rates ISIS Pharm (NASDAQ:ISIS)

Investment analysts at Wells Fargo “Outperform” rating on ISIS Pharm (NASDAQ:ISIS). The firm began coverage on ISISin a very recent research note issued to clients and investors on 4 December.

From a total of 9 analysts covering ISIS Pharmaceuticals (NASDAQ:ISIS) stock, 4 rate it a ”Buy”, 1 a “Sell”, and 5 a ”Hold”. This means that 40% of the ratings are positive. The highest target price is $88 while the lowest target price is $12. The mean of all analyst targets is $65.11 with a 22.18% above today’s ($58.56) stock price. ISIS Pharmaceuticals was the topic of 5 analyst reports since September 8, 2015 according to the firm StockzIntelligence Inc. Goldman Sachs initiated shares on November 18 with “Neutral” rating. Piper Jaffray upgraded ISIS stock in a recent report from November 5 to “Overweight” rating. Finally, Vetr downgraded the stock to “Buy” rating in a report issued on a September 8.

Approximately 372,553 shares of stock traded hands. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) has declined 0.41% since May 1, 2015 and is downtrending. It has outperformed by 2.37% the S&P500.

Isis Pharmaceuticals, Inc. is a Ribonucleic acid-targeted (RNA-targeted) drug discovery and development company. The company has a market cap of $6.96 billion. The Firm is focused to discover and develop antisense drugs. It has 527.09 P/E ratio. The antisense drugs are used to treat a range of diseases, including cardiovascular, metabolic, severe and rare diseases, including neurological disorders and cancer.

According to Zacks Investment Research, “Isis Pharmaceuticals, Inc. is a leading genomics-based drug discovery and development company that is focused on RNA. RNA is a novel target for drug discovery, and Isis has established a dominant position in RNA research. The company has integrated the expertise in molecular and cellular biology, medicinal chemistry, RNA biochemistry, bioinformatics, pharmacology and clinical development to create two exciting technologies, antisense and Ibis, a robust pipeline of drugs in development and genomics services.” Get a free copy of the Zacks research report on ISIS Pharmaceuticals, Inc. (ISIS).